Preclinical studies on an ovarian cancer mouse model clearly showed that an oral dose of PEITC significantly suppressed ovarian cancer tumor growth seemingly by targeting inhibition of the EGFR-Akt pathway [113]. Here, AKT1 is linked to ovarian cancer.